Cryopreservation of therapeutic cells allows the long-term storage of functional cells and prevents degradative processes. Fresh cells are also used for cellular therapy approaches; however, there are many circumstances that make the availability of cryopreserved cells a must for repeated and on-hand use of cells. Cell cryopreservation provides a reliable stock of cells, which reduces the variability of cell therapy product. This translates to a more standardized product that can be used on a larger scale and without constraints on optimal availability for clinical use.
When considering the use of fresh cells that cannot be relied upon for long-term storage due to more rapid degradation of the cell products, strict scheduling requirements are needed. This restricts the days and times cells can be used and a specific schedule would be needed to collect new cells when multiple or repeated cell treatments are necessary. This adds an additional and considerable expense to the cell therapy manufacturing process of a facility and patient delivery in the clinical setting. However, if cryopreserved cells are available and stored, this adds significant convenience for patient treatment and lowers the costs of handling and use.
At the patient level, cryopreservation of cells provides product that can be used at times that are optimal for successful patient responses. That means that patient therapy will not depend on the availability and scheduling of donor cell collection and shipment for use. Cells would be available when the patients need them, and retreatment of a patient can also occur as soon as needed, instead of waiting for new fresh cells to be collected again for a given patient.
Applying cell cryopreservation in the cell therapy development process would essentially provide cell sources that provide little variability between samples. This is a key factor in the maintenance of cell quality and predictability of positive therapeutic effects. Overall, cell cryopreservation streamlines or simplifies the procurement of cells, promotes uniformity of product, allows more flexible patient use, and reduces manufacturing and clinical application costs.
From meeting donor selection criteria to shipping cryopreserved cells, HemaCare can support all your blood product and cell needs.
References:Gaudet, I. (2016). The Cold Truth: Cryopreservation of Final Product in Cell Therapy Manufacturing. Available at: https://www.pctcelltherapy.com/pct-pulse/the-cold-truth-cryopreservation-of-final-product-in-cell-therapy-manufacturing [Accessed 19 Dec. 2017].